Elham Karimi
Research Subjects
Research Interests
Elham Karimi has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Aldo Hernandez-Corchado
Department of Human Genetics, Faculty of Medicine and Health Sciences
1 shared publication - Ali Nehme
Victor Phillip Dahdaleh Institute of Genomic Medicine, and
1 shared publication - Benoit Fiset
Goodman Cancer Institute
1 shared publication - Bridget Liu
Goodman Cancer Institute
1 shared publication - Daniela F. Quail
Rosalind and Morris Goodman Cancer Institute, McGill University, Montreal, Canada
1 shared publication - Emilie Pichette
Department of Pathology, Faculty of Medicine and Health Sciences, and
1 shared publication
Latest Publications
- Open Access
- 26 March 2026
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 11 (10)
Distinct immune landscapes characterize highly versus minimally invasive brain metastases
Brain metastases (BrMs) occur in approximately 30% of cancer patients, causing nearly one-fifth of cancer deaths. While immune checkpoint inhibitors (ICIs) benefit some BrM patients, responses remain highly variable. This variability partly reflects distinct histopathological growth patterns that include minimally invasive (MI) and highly invasive (HI) brain BrMs. Here we show that MI BrMs exhibit robust immune infiltration, whereas HI lesions are immunosuppressed. However, histological differentiation between MI and HI can be challenging because of subjective margin assessment. Here, using highly multiplexed spatial proteomics on 119 tumor sections from 46 patients with BrMs, we identify CHI3L1 as a key mediator of the immunosuppressive microenvironment in HI BrMs. In preclinical models, genetic deletion of CHI3L1 converts immune-cold metastases into lymphocyte-rich, ICI-responsive lesions infiltrated by granzyme B + CD8 + T cells. In BrM patients treated with ICI, immunohistochemical quantification of CHI3L1 expression was a stronger predictor of ICI response than traditional MI/HI classification. Thus, CHI3L1 represents a promising biomarker and therapeutic target for BrMs.
- 26 March 2026
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 11 (10)
Open AccessDistinct immune landscapes characterize highly versus minimally invasive brain metastases
Brain metastases (BrMs) occur in approximately 30% of cancer patients, causing nearly one-fifth of cancer deaths. While immune checkpoint inhibitors (ICIs) benefit some BrM patients, responses remain highly variable. This variability partly reflects distinct histopathological growth patterns that include minimally invasive (MI) and highly invasive (HI) brain BrMs. Here we show that MI BrMs exhibit robust immune infiltration, whereas HI lesions are immunosuppressed. However, histological differentiation between MI and HI can be challenging because of subjective margin assessment. Here, using highly multiplexed spatial proteomics on 119 tumor sections from 46 patients with BrMs, we identify CHI3L1 as a key mediator of the immunosuppressive microenvironment in HI BrMs. In preclinical models, genetic deletion of CHI3L1 converts immune-cold metastases into lymphocyte-rich, ICI-responsive lesions infiltrated by granzyme B + CD8 + T cells. In BrM patients treated with ICI, immunohistochemical quantification of CHI3L1 expression was a stronger predictor of ICI response than traditional MI/HI classification. Thus, CHI3L1 represents a promising biomarker and therapeutic target for BrMs.